EUVIMEDEUVIMED entdecken
Open Access

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas

Kristyn Galbraith iD, Mekka Garcia, Siyu Wei, Anna Chen, Chanel Schroff, Jonathan Serrano, Donato Pacione, Dimitris G Placantonakis, Christopher M William, Arline Faustin, David Zagzag, Marissa Barbaro und 14 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Kristyn Galbraith und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Astrocytoma, DNA Methylation, Isocitrate Dehydrogenase, Cyclin-Dependent Kinase Inhibitor p16. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Friedberg Charitable Foundation, National Instituions of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isocitrate dehydrogenase (IDH) mutant astrocytoma grading, until recently, has been entirely based on morphology. The 5th edition of the Central Nervous System World Health Organization (WHO) introduces CDKN2A/B homozygous deletion as a biomarker of grade 4. We sought to investigate the prognostic impact of DNA methylation-derived molecular biomarkers for IDH mutant astrocytoma.

Methods

We analyzed 98 IDH mutant astrocytomas diagnosed at NYU Langone Health between 2014 and 2022. We reviewed DNA methylation subclass, CDKN2A/B homozygous deletion, and ploidy and correlated molecular biomarkers with histological grade, progression free (PFS), and overall (OS) survival. Findings were confirmed using 2 independent validation cohorts.

Results

There was no significant difference in OS or PFS when stratified by histologic WHO grade alone, copy number complexity, or extent of resection. OS was significantly different when patients were stratified either by CDKN2A/B homozygous deletion or by DNA methylation subclass (P value = .0286 and .0016, respectively). None of the molecular biomarkers were associated with significantly better PFS, although DNA methylation classification showed a trend (P value = .0534).

Conclusions

The current WHO recognized grading criteria for IDH mutant astrocytomas show limited prognostic value. Stratification based on DNA methylation shows superior prognostic value for OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaDNA MethylationIsocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16MutationBiomarkers, TumorBrain NeoplasmsHumansMalePrognosisFemaleMiddle AgedAdultCyclin-Dependent Kinase Inhibitor p15AgedSurvival RateFollow-Up StudiesYoung AdultHomozygoteGene Deletion

Stichwörter der Autor:innen

DNA methylationIDH mutant astrocytomagradingmolecularprognosis

Substanzen

Isocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16CDKN2A protein, humanBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p15CDKN2B protein, human

Autor:innen und Institutionen

  • Department of Pathology, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Neurology, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Biostatistics, NYU School of Global Public Health, New York, New York, USA.
  • Department of Radiology, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.
  • Department of Neuro-oncology, NYU Langone Health and NYU Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Kristyn Galbraith, Mitsuaki Shirahata, David Reuss, Andreas von Deimling, Brent A Orr, Matija Snuderl

Förderung

  • NINDS NIH HHS
  • Friedberg Charitable Foundation
  • National Instituions of Health
  • NCI NIH HHS
  • Making Headway Foundation
  • Gray Family Foundation

Zitieren

APA

Galbraith, K., Garcia, M., Wei, S., Chen, A., Schroff, C., Serrano, J., Pacione, D., Placantonakis, D. G., William, C. M., Faustin, A., Zagzag, D., Barbaro, M., Eibl, M. D. P. G. P., Shirahata, M., Reuss, D., Tran, Q. T., Alom, Z., von Deimling, A., Orr, B. A., …, & Snuderl, M. (2024). Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae009

Vancouver

Galbraith K, Garcia M, Wei S, Chen A, Schroff C, Serrano J, et al. Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae009

BibTeX
@article{Galbraith2024,
  author = {Galbraith, Kristyn and Garcia, Mekka and Wei, Siyu and Chen, Anna and Schroff, Chanel and Serrano, Jonathan and Pacione, Donato and Placantonakis, Dimitris G and William, Christopher M and Faustin, Arline and Zagzag, David and Barbaro, Marissa and Eibl, Maria Del Pilar Guillermo Prieto and Shirahata, Mitsuaki and Reuss, David and Tran, Quynh T and Alom, Zahangir and von Deimling, Andreas and Orr, Brent A and Sulman, Erik P and Golfinos, John G and Orringer, Daniel A and Jain, Rajan and Lieberman, Evan and Feng, Yang and Snuderl, Matija},
  title = {Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae009}
}
Kostenlos starten →